PDA Offers Help in Applying Single-Use Systems to Bio/Pharma Operations
Technical Report No. 66: Application of Single-Use Systems in Pharmaceutical Manufacturing now available
BETHESDA, Md., Oct. 16, 2014 /PRNewswire-USNewswire/ -- The Parenteral Drug Association (PDA) announces the completion of guidance on the application of single-use, or disposable, systems in the manufacturing operations for pharmaceutical and biopharmaceutical products with the publication of Technical Report No. 66: Application of Single-Use Systems in Pharmaceutical Manufacturing.
Single-use technology, often described as single-use systems (SUS) or single-use equipment, has the potential to transform pharmaceutical manufacturing by offering tremendous opportunities to reduce cost, improve flexibility or cycle time, and shorten the time needed to build a manufacturing process for new, life-saving drugs. This success, however, is very much dependent on how effectively the industry approaches the development and implementation of single-use technology.
PDA Technical Report No. 66: Application of Single-Use Systems in Pharmaceutical Manufacturing is intended to provide the reader with critical concepts or points to consider when implementing an SUS strategy in a pharmaceutical manufacturing process. These concepts are intended to be valid both for chemically synthesized small molecules and for bioprocesses that produce large-molecule biopharmaceutical products.
"PDA thanks the task force team of volunteers that produced Technical Report No. 66 for their hard work in ensuring that the document represents the most up-to-date best practices in the application of single-use systems," said PDA President Richard Johnson. "The task force team of authors and contributors was diverse, representing large and small drug manufacturers, vendors to the industry and even the U.S. FDA."
The team of authors was:
| Robert Repetto, Team Co-Chair, Pfizer |
Duncan Low, Ph.D., Amgen |
| Morten Munk, Team Co-Chair, CMC Biologics |
Ingrid Markovic, Ph.D., U.S. FDA |
| Stephen Brown, Ph.D., BE Vaccines |
Jerold Martin, Pall Life Sciences |
| Jeffrey Carter, Ph.D., GE Healthcare |
Paul Priebe, Sartorius Stedim Biotech |
| Niels Guldager, NNE Pharmaplan |
Christopher J. Smalley, Ph.D., Merck & Co |
| Christian Julien, Meissner Filtration Products, Inc. |
Russell Wong, Ph.D., Bayer HealthCare |
Contributors to the document were:
| Robin Alonso, Genentech |
James Robinson, Lachman Consultants |
| Eberhard Bill, Ph.D., Boehringer Ingelheim |
Hillary Russak, Genentech |
| Oki Dzivenu, GE Healthcare |
Robert Shaw, Finvector—FVT Ltd |
| Bill Hartzel, Catalent Pharma Solutions |
Ken Baker, NewAge Industries Inc. |
| Eric Isberg, ATMI |
Sally Kline, Ph.D., Amgen |
| Maik Jornitz, G-Con |
Mani Krishnan, EMD Millipore |
| Michael Kraich, Ph.D., Boehringer Ingelheim |
Jessica Frantz, Sartorius Stedim Biotech |
About PDA – Connecting People, Science and Regulation®
The Parenteral Drug Association (PDA) is the leading global provider of science, technology and regulatory information and education for the pharmaceutical and biopharmaceutical community. Founded in 1946 as a nonprofit organization, PDA is committed to developing scientifically sound, practical technical information and resources to advance science and regulation through the expertise of its more than 9,500 members worldwide. Go to http://www.pda.org/footer/about-pda to learn more.
Media Inquiries: Walt Morris, 301-656-5900, x. 148; [email protected]
Logo - http://photos.prnewswire.com/prnh/20130226/DC66667LOGO
SOURCE Parenteral Drug Association
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article